China is a high prevalence area for chronic Hepatitis B virus （CHB） infection， which has caused significant harm to public health and imposed a substantial economic burden. Due to differences in main transmission routes， genetic backgrounds， and virus genotypes between China and regions like Europe and the United States， more than 80% of hepatocellular carcinoma （HCC） occurrences in China are associated with chronic Hepatitis B （CHB）. Additionally， the number of new HCC cases and the number of patients who die from HCC each year in China account for nearly half of the global figures. Antiviral therapy is an important measure to block or delay the progression of HBV-related liver diseases and reduce the occurrence of HCC， and the only indicator that can bring long-term good outcomes for patients is the disappearance of HBsAg. HBsAg loss has become the ideal therapeutic point for chronic HBV antiviral therapy. As the efficacies of antiviral therapy is affected by multiple factors， in order to improve the incidence of HBsAg disappearance with existing antiviral drugs， it is necessary to optimize treatment according to the situation of patients， including advantageous patient selection， combination therapy of PEG-IFN and NA， extended therapy， intermittent therapy， and consolidation therapy after HBsAg disappearance. This article discussed the optimal treatment strategy of antiviral therapy for chronic HBV infection in pursuit of HBsAg disappearance， and provided reference for clinical practice.